UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
------------------------
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
------------------------
Date of Report (Date of earliest event reported): December 30, 2003
IMPAX LABORATORIES, INC.
----------------------------------------------------------------
(Exact name of Registrant as specified in its charter)
Delaware 0-27354 65-0403311
- ------------------------------- ----------------- ----------------------
(State or other jurisdiction of (Commission (I.R.S. Employer
incorporation or organization) File Number) Identification Number)
30381 Huntwood Avenue
Hayward, CA 94544
------------------------------------------------------------
(Address of principal executive offices, including zip code)
Registrant's telephone number, including area code: (510) 476-2000
--------------
Item 9. Regulation FD Disclosure
On December 30, 2003, Impax Laboratories, Inc. issued a press release
announcing that Shire Laboratories Inc. had filed a lawsuit against the Company
in the federal district court in Delaware alleging patent infringement related
to Impax's filing of an Abbreviated New Drug Application (ANDA) for a generic
version of 30 mg Adderall XR, an extended release Attention Deficit
Hyperactivity Disorder medicine. A copy of the press release is attached as
Exhibit 99.1 and is incorporated herein by reference.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Impax Laboratories, Inc.
Date: December 30, 2003
By: /s/ Barry R. Edwards
----------------------------
Barry R. Edwards
Co-Chief Executive Officer